GlassScriptPhysician profile
Shuang Fu
NPI 1730495342
$4,679.73
in general payments reported to CMS, 2019-2025
46 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $217 · 2021: $371 · 2022: $540 · 2023: $714 · 2024: $1,152 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Education: $86.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.57 |
| Education | $86.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $421.85 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $346.81 | 2021-2025 | Darzalex, Carvykti, Balversa |
| Pfizer INC. | $307.93 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $249.32 | 2022-2024 | Tavalisse, Rezlidhia |
| Amgen INC. | $231.32 | 2020-2025 | Imdelltra (Amg757), Lumakras |
| Eisai INC. | $230.00 | 2020-2024 | |
| Abbvie INC. | $228.90 | 2019-2025 | |
| Incyte Corporation | $219.11 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $197.10 | 2023-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $181.95 | 2021-2025 | |
| Beone Medicines USA, INC. | $168.47 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $162.97 | 2023-2025 | Enhertu, Injectafer |
| Stemline Therapeutics INC. | $146.63 | 2023-2025 | Orserdu |
| Genzyme Corporation | $136.18 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $123.77 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $107.72 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $104.41 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $93.18 | 2021-2025 | Imfinzi, Enhertu |
| Beigene USA, INC. | $90.80 | 2022-2024 | Brukinsa |
| Celgene Corporation | $81.23 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $69.79 | 2019-2023 | Adcetris |
| Agios Pharmaceuticals, INC. | $50.12 | 2023-2024 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2024 | Onivyde |
| Tempus Ai, INC | $46.57 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Lilly USA, LLC | $40.35 | 2024 | Verzenio, Jaypirca |
| Array Biopharma INC | $35.28 | 2025 | Tukysa, Mektovi, Braftovi |
| Tersera Therapeutics LLC | $33.14 | 2023-2025 | Zoladex |
| Coherus Oncology, INC. | $30.73 | 2023-2024 | |
| Springworks Therapeutics, INC. | $30.56 | 2024 | Ogsiveo |
| Sobi, INC | $30.16 | 2025 | |
| Gilead Sciences, INC. | $26.17 | 2021-2022 | |
| Caris Mpi, INC. | $23.53 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $22.77 | 2025 | Xpovio |
| Genmab U.S., INC. | $22.27 | 2024 | Epkinly |
| Legend Biotech USA INC. | $21.94 | 2024 | |
| Emd Serono, INC. | $19.28 | 2025 | |
| Genentech USA, INC. | $19.18 | 2023 | Venclexta |
| Aveo Pharmaceuticals, INC. | $18.59 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.06 | 2023 | Qinlock |
| Taiho Oncology, INC. | $17.30 | 2023 | |
| Puma Biotechnology, INC. | $16.87 | 2025 | |
| Cti Biopharma Corp. | $15.57 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $12.51 | 2022 | |
| Exelixis INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuang Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.